Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity

By Dilts D.A.   Riesenfeld-Orn I.   Fulginiti J.P.   Ekwall E.   Granert C.   Nonenmacher J.   Brey R.N.   Cryz S.J.   Karlsson K.   Bergman K.   Thompson T.   Hu B.   Bruckner A.H.   Lindberg A.A.  

Vaccine, Vol. 18, Iss. 15, 2000-02 ,pp. : 1473-1484

Elsevier

Access to resources Recommend Favorite

Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2

By Kotloff K.L.   Losonsky G.A.   Nataro J.P.   Wasserman S.S.   Hale T.L.   Taylor D.N.   Newland J.W.   Sadoff J.C.   Formal S.B.   Levine M.M.  

Vaccine, Vol. 13, Iss. 5, 1995-01 ,pp. : 495-502

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers

By DiPetrillo M.D.   Tibbetts T.   Kleanthous H.   Killeen K.P.   Hohmann E.L.  

Vaccine, Vol. 18, Iss. 5, 1999-10 ,pp. : 449-459

Elsevier

Access to resources Recommend Favorite

Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers

By Hohmann E.L.   Oletta C.A.   Miller S.I.  

Vaccine, Vol. 14, Iss. 1, 1996-01 ,pp. : 19-24

Elsevier

Access to resources Recommend Favorite

Construction and characterization of virG (icsA)-deleted Escherichia coli K12-Shigella flexneri hybrid vaccine strains

By Alexander W.A.   Hartman A.B.   Oaks E.V.   Venkatesan M.M.  

Vaccine, Vol. 14, Iss. 11, 1996-08 ,pp. : 1053-1061

Elsevier

Access to resources Recommend Favorite